Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
$0.01
$0.00
$3.46
$16K-2.3951,674 shsN/A
Conformis, Inc. stock logo
CFMS
Conformis
$2.26
$2.25
$1.05
$7.25
$17.80M1.3999,585 shs7,000 shs
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
$5.41
+0.2%
$5.25
$4.22
$8.90
$61.94M0.248,114 shs1,040 shs
Histogenics Corp stock logo
HSGX
Histogenics
$1.18
-5.6%
$1.33
$0.08
$1.43
$111.63M3.19.06 million shs7.25 million shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.18
-5.6%
$1.27
$0.35
$2.11
$303.65M3.518.10 million shs7.25 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
0.00%0.00%0.00%0.00%+7,380.00%
Conformis, Inc. stock logo
CFMS
Conformis
0.00%0.00%0.00%0.00%+43.95%
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
+2.66%+5.06%+5.88%-0.74%-23.40%
Histogenics Corp stock logo
HSGX
Histogenics
+0.81%-21.38%-23.78%+134.21%+73.61%
Ocugen, Inc. stock logo
OCGN
Ocugen
+0.81%-21.38%-23.78%+128.81%+73.61%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
N/AN/AN/AN/AN/AN/AN/AN/A
Conformis, Inc. stock logo
CFMS
Conformis
N/AN/AN/AN/AN/AN/AN/AN/A
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
1.5536 of 5 stars
3.53.00.00.01.90.00.6
Histogenics Corp stock logo
HSGX
Histogenics
N/AN/AN/AN/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
0.8778 of 5 stars
3.51.00.00.02.90.00.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
N/AN/AN/AN/A
Conformis, Inc. stock logo
CFMS
Conformis
2.00
HoldN/AN/A
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
3.00
Buy$11.00103.33% Upside
Histogenics Corp stock logo
HSGX
Histogenics
N/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
3.00
Buy$4.67295.48% Upside

Current Analyst Ratings

Latest CFMS, CLGN, HSGX, AHPI, and OCGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
Ocugen, Inc. stock logo
OCGN
Ocugen
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $5.00
4/5/2024
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00
4/3/2024
Ocugen, Inc. stock logo
OCGN
Ocugen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
2/22/2024
Ocugen, Inc. stock logo
OCGN
Ocugen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
1/24/2024
Ocugen, Inc. stock logo
OCGN
Ocugen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$5.00 ➝ $7.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
$27.05M0.00N/AN/A$1.30 per share0.00
Conformis, Inc. stock logo
CFMS
Conformis
$57.06M0.31N/AN/A$4.07 per share0.56
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
$10.96M5.65N/AN/A$2.47 per share2.19
Histogenics Corp stock logo
HSGX
Histogenics
N/AN/AN/AN/A($0.01) per shareN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
$6.04M50.27N/AN/A$0.16 per share7.38

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
-$5.36M-$1.34N/AN/AN/AN/AN/AN/AN/A
Conformis, Inc. stock logo
CFMS
Conformis
-$50.47M-$5.61N/AN/AN/A-72.72%-86.46%-47.65%N/A
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
-$7.02M-$0.64N/AN/AN/A-64.05%-22.17%-18.84%5/22/2024 (Estimated)
Histogenics Corp stock logo
HSGX
Histogenics
-$8.64M-$0.79N/AN/AN/A-34.96%18.40%N/A
Ocugen, Inc. stock logo
OCGN
Ocugen
-$63.08M-$0.27N/AN/AN/AN/A-102.97%-77.75%5/3/2024 (Estimated)

Latest CFMS, CLGN, HSGX, AHPI, and OCGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/16/2024Q4 2023
Ocugen, Inc. stock logo
OCGN
Ocugen
N/A-$0.04-$0.04-$0.04N/A$6.04 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
N/AN/AN/AN/AN/A
Conformis, Inc. stock logo
CFMS
Conformis
N/AN/AN/AN/AN/A
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
N/AN/AN/AN/AN/A
Histogenics Corp stock logo
HSGX
Histogenics
N/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
N/AN/AN/A
Conformis, Inc. stock logo
CFMS
Conformis
0.64
5.07
3.30
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
N/A
8.62
8.40
Histogenics Corp stock logo
HSGX
Histogenics
N/A
4.05
4.05
Ocugen, Inc. stock logo
OCGN
Ocugen
0.07
2.51
2.51

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
4.15%
Conformis, Inc. stock logo
CFMS
Conformis
10.31%
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
21.69%
Histogenics Corp stock logo
HSGX
Histogenics
40.35%
Ocugen, Inc. stock logo
OCGN
Ocugen
10.27%

Insider Ownership

CompanyInsider Ownership
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
5.10%
Conformis, Inc. stock logo
CFMS
Conformis
3.80%
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
9.60%
Histogenics Corp stock logo
HSGX
Histogenics
19.70%
Ocugen, Inc. stock logo
OCGN
Ocugen
3.48%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Allied Healthcare Products, Inc. stock logo
AHPI
Allied Healthcare Products
1894.01 million3.81 millionNot Optionable
Conformis, Inc. stock logo
CFMS
Conformis
2957.88 million7.58 millionNot Optionable
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
7311.45 million10.35 millionOptionable
Histogenics Corp stock logo
HSGX
Histogenics
4994.60 millionN/ANot Optionable
Ocugen, Inc. stock logo
OCGN
Ocugen
84257.33 million248.37 millionOptionable

CFMS, CLGN, HSGX, AHPI, and OCGN Headlines

SourceHeadline
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmDEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
accesswire.com - April 24 at 6:45 PM
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmIMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
prnewswire.com - April 23 at 11:30 AM
Ocugen (NASDAQ:OCGN) Price Target Increased to $5.00 by Analysts at Chardan CapitalOcugen (NASDAQ:OCGN) Price Target Increased to $5.00 by Analysts at Chardan Capital
americanbankingnews.com - April 23 at 3:32 AM
Ocugen (NASDAQ:OCGN) Given New $5.00 Price Target at Chardan CapitalOcugen (NASDAQ:OCGN) Given New $5.00 Price Target at Chardan Capital
marketbeat.com - April 22 at 8:29 AM
Key Takeaways From Ocugen Analyst RatingsKey Takeaways From Ocugen Analyst Ratings
markets.businessinsider.com - April 22 at 8:19 AM
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmDEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
accesswire.com - April 22 at 7:00 AM
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OcugenSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
markets.businessinsider.com - April 21 at 10:14 AM
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmDEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
accesswire.com - April 21 at 7:00 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGNSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN
prnewswire.com - April 20 at 11:00 AM
Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive ValueOcugen: Two Gene Therapy Data Readouts In 2024 To Drive Value
seekingalpha.com - April 19 at 8:04 PM
OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
prnewswire.com - April 19 at 12:00 PM
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene TherapyOcugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
globenewswire.com - April 19 at 7:13 AM
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmDEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
accesswire.com - April 19 at 7:00 AM
Ocugen stock jumps after $175M securities filingOcugen stock jumps after $175M securities filing
msn.com - April 18 at 9:05 AM
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
accesswire.com - April 18 at 9:00 AM
Ocugen, Inc. (OCGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsOcugen, Inc. (OCGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
stockhouse.com - April 18 at 12:44 AM
ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGNROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
prnewswire.com - April 17 at 11:00 PM
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
markets.businessinsider.com - April 17 at 2:44 PM
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmIMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
prnewswire.com - April 17 at 1:51 PM
Ocugen (OCGN) Price Target Decreased by 15.79% to 5.44Ocugen (OCGN) Price Target Decreased by 15.79% to 5.44
msn.com - April 17 at 9:43 AM
OCGN Stock Earnings: Ocugen Beats EPS for Q4 2023OCGN Stock Earnings: Ocugen Beats EPS for Q4 2023
msn.com - April 17 at 12:32 AM
3 Standout Penny Stocks to Watch This April3 Standout Penny Stocks to Watch This April
msn.com - April 16 at 2:32 PM
Short Interest in Ocugen, Inc. (NASDAQ:OCGN) Grows By 22.8%Short Interest in Ocugen, Inc. (NASDAQ:OCGN) Grows By 22.8%
marketbeat.com - April 15 at 5:09 PM
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
accesswire.com - April 15 at 12:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Allied Healthcare Products logo

Allied Healthcare Products

NASDAQ:AHPI
Allied Healthcare Products, Inc. engages in manufacturing respiratory products used in the health care industry in hospitals and alternate site settings, including sub-acute care facilities, home health care and emergency medical care. Its product line includes respiratory care products, medical gas equipment, and emergency medical products. The company was founded in 1979 and is headquartered in St. Louis, MO.
Conformis logo

Conformis

NASDAQ:CFMS
Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, iTotal CR, and iTotal PS, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also offers Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Brazil, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.
CollPlant Biotechnologies logo

CollPlant Biotechnologies

NASDAQ:CLGN
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; Tel Aviv University; Sheba Medical Center; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Histogenics logo

Histogenics

NASDAQ:HSGX
Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.
Ocugen logo

Ocugen

NASDAQ:OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.